1079 Discovery of a novel DLL3/CD3 bispecific T cell engager for treating SCLC

Li Li, Ye Feng, Mengqiu Xu, Huijun Sha, Min Wu, Dian Kang, Zhihui Kuang, Mengjia Zhu, Jian Zhang, Zhihai Wu, Ying Zhang, Shuaixiang Zhou, Bingliang Chen, Kevin He, Weiwei WuRegular 2024 · DOI

Introduction

Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat malignancies, representing approximately 15% of all lung cancer cases. Characterized by rapid doubling time and early systemic metastasis, SCLC is often categorized as a "recalcitrant" cancer due to the lack of effective long-term treatment options.

Delta-like ligand 3 (DLL3) has emerged as a highly promising therapeutic target for this disease. While DLL3 is primarily localized intracellularly in normal tissues, it is significantly overexpressed on the cell surface of SCLC and other high-grade neuroendocrine cancers (NECs). This differential expression provides a specific molecular "address" for targeted immunotherapy, allowing for the recruitment of the immune system directly to the tumor site.

IAR025: Design and Mechanism of Action

In this study, researchers developed IAR025, a novel bispecific T-cell engager (BiTE) designed to bridge DLL3-expressing tumor cells with CD3-expressing T cells. IAR025 utilizes a "1+1 asymmetry" structure, featuring one fragment antigen-binding (Fab) region for DLL3 and another for CD3.

A critical design feature of IAR025 is its affinity tuning. The antibody was engineered with a higher affinity for human DLL3 (0.7 nM) than for human CD3 (3.26 nM). This "affinity sink" strategy is intended to optimize biodistribution; by binding more strongly to the tumor target than to circulating T cells, the molecule is less likely to be sequestered in the peripheral blood, allowing for better penetration and accumulation within the tumor microenvironment.

Experimental Methodology

The efficacy and safety of IAR025 were evaluated through a comprehensive preclinical pipeline:

  • In Vitro Potency: Researchers assessed dose-dependent cytotoxicity using SCLC cell lines (DMS79 and SHP-77) co-cultured with human primary effector cells.
  • In Vivo Efficacy: Humanized xenograft models were employed using NOG mice engrafted with human peripheral blood mononuclear cells (PBMCs) to provide a functional human immune component against implanted SCLC tumors.
  • Pharmacokinetics and Safety: The drug’s metabolic profile was studied in mice, while its safety, toxicokinetics, and potential for cytokine release syndrome (CRS) were evaluated in cynomolgus monkeys—a standard model for predicting human responses to bispecific antibodies.

Key Results

High Specificity and Potency

In vitro assays demonstrated that IAR025 induces the dose-dependent eradication of DLL3-positive SCLC cells. Notably, the treatment showed no non-specific cell destruction in DLL3-negative cells even at high concentrations (up to 900 nM), suggesting a wide therapeutic window and high target specificity.

Complete Tumor Regression

In animal models, IAR025 treatment led to a significant increase in tumor-infiltrating human CD3+ T cells. This influx effectively converted "cold" SCLC tumors into immunologically "hot" environments. In both DMS79 and SHP-77 xenograft models, this T-cell recruitment resulted in complete tumor regression.

Favorable Pharmacokinetics and Safety Profile

IAR025 exhibited an IgG-like pharmacokinetic profile with a clearance rate of 0.4 ml/kg/h in mice, suggesting the potential for sustained therapeutic levels in vivo. In safety trials involving cynomolgus monkeys, the drug was well-tolerated at doses up to 10 mg/kg across three consecutive administrations. Crucially, no histopathological abnormalities or signs of cytokine release syndrome—a common complication with T-cell engagers—were detected during the preliminary toxicological evaluation.

Discussion and Future Directions

The preclinical data for IAR025 suggests it is a highly efficacious and safe candidate for the treatment of SCLC. By prioritizing tumor binding over T-cell binding, the researchers have addressed a common hurdle in bispecific antibody design, potentially improving the drug's ability to reach solid tumors without systemic over-activation of the immune system.

However, while these results are robust, the transition to human clinical trials remains the critical next step. Future research must determine if the complete regressions seen in mouse models translate to durable responses in patients, particularly given the complex immunosuppressive environments often found in human SCLC. Additionally, long-term studies will be needed to monitor for potential resistance mechanisms, such as the downregulation of DLL3 expression.

Conclusion

IAR025 represents a significant advancement in the development of T-cell engaging therapies for neuroendocrine cancers. Its combination of high specificity, potent anti-tumor activity, and a manageable safety profile makes it a strong candidate for clinical evaluation in patients with DLL3-positive Small Cell Lung Cancer.

Summary updated

Abstract

<h3>Background</h3> Small cell lung cancer (SCLC) is an aggressive tumor type with limited treatment options, which represents around 15% of all lung cancers. Delta-like ligand 3 (DLL3) has emerged as an attractive target overexpressed on the cell surface of SCLC and other high-grade neuroendocrine cancers (NECs). <h3>Methods</h3> IAR025 is a bispecific antibody with 1+1 asymmetry, comprising two binding domains: a fragment antigen-binding (Fab) region that recognizes DLL3 on tumor cells and another Fab that binds to CD3 on T cells. The efficacy and mode of action of IAR025 were assessed <i>in vitro</i> using SCLC cell lines and human primary effector cells, as well as in humanized xenograft models <i>in vivo</i>. The tolerability and toxicokinetic properties of IAR025 were studied in cynomolgus monkeys. <h3>Results</h3> IAR025 was designed to have higher affinity to human DLL3 (0.7nM) than human CD3 (3.26nM) to increase tumor biodistribution. IAR025 resulted in a dose-dependent eradication of DLL3 positive SCLC cells, without nonspecific cell destruction in DLL3 negative cells up to 900nM in vitro. In animal models, IAR025 treatment induced a significant increase of tumor infiltrating human CD3+ T cells, leading to complete tumor regressions in DMS79 and SHP-77 xenograft tumors in NOG mice engrafted with human PBMCs. Moreover, IAR025 demonstrated a IgG-like PK profile with clearance at 0.4 ml/kg/h in mouse. Notably, in cynomolgus monkeys, IAR025 was well-tolerated at doses up to 10 mg/kg following three consecutive administrations, with no indications of cytokine release or histopathological abnormalities detected during the preliminary toxicological evaluation. <h3>Conclusions</h3> Pre-clinic efficacy and toxicity study suggests IAR025 is a highly efficacious and safe T cell engager for treating small cell lung cancer.
BibTeX
@inproceedings{li2024discovery,
  author = {Li Li and Ye Feng and Mengqiu Xu and Ninghuan Li and Huijun Sha and Min Wu and Dian Kang and Zhihui Kuang and Mengjia Zhu and Jian Zhang and Zhihai Wu and Ying Zhang and Shuaixiang Zhou and Bingliang Chen and Kevin He and Weiwei Wu},
  title = {{1079 Discovery of a novel DLL3/CD3 bispecific T cell engager for treating SCLC}},
  booktitle = {Regular},
  year = {2024},
  doi = {10.1136/jitc-2024-sitc2024.1079},
}
Figure